Duloxetine in the treatment of irritable bowel syndrome: an open‐label pilot study
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: To assess the efficacy of duloxetine for irritable bowel syndrome (IBS). Methods: We conducted an open‐label 12‐week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder. The primary outcome measure was average abdominal pain. Secondary measures included IBS symptoms, Clinical Global Impression‐Severity, Hamilton Anxiety Rating Scale, IBS Quality‐of‐Life Scale, and Sheehan Disability Scale. We analyzed changes using random regression and one‐sample t‐tests. Results: Fourteen patients completed at least one post‐baseline evaluation; eight completed the study. Duloxetine was associated with significant improvement (p < 0.05) in pain, severity of illness, quality of life, loose stool, work and family disability, and anxiety. However, duloxetine did not improve hard stool. Although we found no evidence of serious duloxetine toxicity, seven participants withdrew over the course of the study because of adverse drug events. Conclusions: In this small, open‐label study, duloxetine appeared to be effective for many features of IBS, but its adverse effects, most notably constipation, limited its use. Since our study excluded individuals with concurrent major depression, it appears that duloxetine may benefit IBS independently of its antidepressant effects. These encouraging but preliminary open‐label findings support further investigation of duloxetine treatment in placebo‐controlled trials of IBS. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional gastrointestinal disorders and the Rome III process
Drossman, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.008 · Cited by 2,416
Endocrinology of the stress response
Charmandari, E., Tsigos, C., & Chrousos, G. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.67.040403.120816 · Cited by 1,799
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Drossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614
Arnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471
V. Stress and irritable bowel syndrome
Mayer, E. A., Naliboff, B. D., Chang, L., & Coutinho, S. V. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.280.4.g519 · Cited by 413
The placebo effect in irritable bowel syndrome trials: a meta‐analysis1
Patel, S. M., Stason, W. B., Legedza, A., Ock, S. M., Kaptchuk, T. J., Conboy, L., Canenguez, K., Park, J. K., Kelly, E., Jacobson, E., et al. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00650.x · Cited by 285
Morgan, V (2005) · Gut · doi:10.1136/gut.2004.047423 · Cited by 269
The economic impact of irritable bowel syndrome
Inadomi, J. M., Fennerty, M. B., & Bjorkman, D. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.t01-1-01736.x · Cited by 190
Stout, S. C., Owens, M. J., & Nemeroff, C. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1085 · Cited by 117
Cited by
Serotonin, tryptophan metabolism and the brain-gut-microbiome axis
O’Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G., & Cryan, J. F. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.027 · Cited by 2,012
Drossman, D. A., Tack, J., Ford, A. C., Szigethy, E., Törnblom, H., & Van Oudenhove, L. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.279 · Cited by 470
Review article: current treatment options and management of functional dyspepsia
Lacy, B. E., Talley, N. J., Locke, G. R., Bouras, E. P., DiBaise, J. K., El‐Serag, H. B., Abraham, B. P., Howden, C. W., Moayyedi, P., & Prather, C. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05128.x · Cited by 192
Opioid misuse in gastroenterology and non-opioid management of abdominal pain
Szigethy, E., Knisely, M., & Drossman, D. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.141 · Cited by 117
Pain management in patients with inflammatory bowel disease: insights for the clinician
Srinath, A. I., Walter, C., Newara, M. C., & Szigethy, E. M. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12446158 · Cited by 111
“In a small openlabel trial, Brennan and colleagues noted 12 weeks of duloxetine (60 mg per day) significantly ameliorated abdominal pain in adults with IBS who were not depressed [Brennan et al. 2009].”
Background
Metadata
- Authors
- Brennan, B. P., Fogarty, K. V., Roberts, J. L., Reynolds, K. A., Pope, H. G., & Hudson, J. I.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2009-06-22
- Volume
- 24
- Issue
- 5
- Pages
- 423-428
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2137924300
- Cited by
- 99
- References
- 10
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duloxetine in the treatment of irritable bowel syndrome: an open‐label pilot study. https://app.cochat.ai/papers/10.1002/hup.1038
- The paper
- Brennan, B. P., Fogarty, K. V., Roberts, J. L., Reynolds, K. A., Pope, H. G., & Hudson, J. I. (2009). Duloxetine in the treatment of irritable bowel syndrome: an open‐label pilot study. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.1038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.